CN115894597A - Extraction process and application of madecassoside with multiple repair effects - Google Patents
Extraction process and application of madecassoside with multiple repair effects Download PDFInfo
- Publication number
- CN115894597A CN115894597A CN202211370486.9A CN202211370486A CN115894597A CN 115894597 A CN115894597 A CN 115894597A CN 202211370486 A CN202211370486 A CN 202211370486A CN 115894597 A CN115894597 A CN 115894597A
- Authority
- CN
- China
- Prior art keywords
- madecassoside
- ethanol
- extraction process
- test
- multiple repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 title claims abstract description 82
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 title claims abstract description 76
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 title claims abstract description 76
- 229940090813 madecassoside Drugs 0.000 title claims abstract description 76
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 238000000605 extraction Methods 0.000 title claims abstract description 25
- 230000008439 repair process Effects 0.000 title claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000000047 product Substances 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 244000146462 Centella asiatica Species 0.000 claims abstract description 10
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 7
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 6
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000012043 crude product Substances 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 238000007670 refining Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 18
- 208000009043 Chemical Burns Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 208000018380 Chemical injury Diseases 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 230000003266 anti-allergic effect Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000011085 pressure filtration Methods 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 231100000344 non-irritating Toxicity 0.000 abstract description 3
- 230000000474 nursing effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 74
- 241000251468 Actinopterygii Species 0.000 description 46
- 210000000440 neutrophil Anatomy 0.000 description 38
- 239000000243 solution Substances 0.000 description 26
- 210000002257 embryonic structure Anatomy 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 23
- 210000001161 mammalian embryo Anatomy 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 241000252212 Danio rerio Species 0.000 description 19
- 235000013601 eggs Nutrition 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 229940059958 centella asiatica extract Drugs 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000238426 Anostraca Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- YCUVUDODLRLVIC-UHFFFAOYSA-N Sudan black B Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1N=NC(C1=CC=CC=C11)=CC=C1N=NC1=CC=CC=C1 YCUVUDODLRLVIC-UHFFFAOYSA-N 0.000 description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 229910000365 copper sulfate Inorganic materials 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 241001672739 Artemia salina Species 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229910052927 chalcanthite Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/10—Process efficiency
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有多重修护功效的羟基积雪草苷的提取工艺及应用,包括以下步骤:S1、将积雪草全草粉碎进行搅拌提取;S2、通过压滤,并进行药液上树脂柱吸附,用乙醇将有效成分从树脂柱洗脱出来;S3、通过将药液上脱色树脂柱,对药液进行脱色,脱色液经刮板浓缩器浓缩至稠膏;S4、转至D级洁净区的微波干燥箱进行烘干;S5、通过粉碎、过筛、总混,即得积雪草总苷;S6、将乙醇溶解分离积雪草苷,得到羟基积雪草苷粗品;S7、通过95%乙醇溶解精制,烘干,粉碎过筛网后,即得羟基积雪草苷。根据本发明,获得不同舒缓修护功效体现的羟基积雪草苷,纯度高,安全无刺激,特别适合应用在儿童保湿及多重修护功效的护理产品中。
The invention discloses an extraction process and application of madecassoside with multiple repairing effects, comprising the following steps: S1, crushing the whole Centella asiatica and extracting it by stirring; Adsorb on the resin column, and elute the active ingredient from the resin column with ethanol; S3, decolorize the medicinal liquid by putting the medicinal liquid on the decolorizing resin column, and the decolorizing liquid is concentrated to a thick paste by a scraper concentrator; S4, go to Drying in a microwave oven in a D-level clean area; S5, crushing, sieving, and total mixing to obtain total asiaticoside; S6, dissolving ethanol to separate asiaticoside to obtain a crude product of madecassoside; S7. Dissolving and refining with 95% ethanol, drying, pulverizing and passing through a sieve to obtain madecassoside. According to the present invention, madecassoside with different soothing and repairing effects is obtained, which is high in purity, safe and non-irritating, and is especially suitable for use in nursing products with moisturizing and multiple repairing effects for children.
Description
技术领域technical field
本发明涉及中药制备的技术领域,特别涉及一种具有多重修护功效的羟基积雪草苷的提取工艺及应用。The invention relates to the technical field of traditional Chinese medicine preparation, in particular to an extraction process and application of madecassoside with multiple repairing functions.
背景技术Background technique
积雪草Centella asiatica(L.)Urban为伞形科多年生草本植物,含有氨基酸类、黄酮类、三萜类等组成成分。羟基积雪草苷(madecassoside,MC)是积雪草中含量最高的五环类三萜化合物,分子式为C48H78O20,相对分子质量975.13,外观形状为白色结晶。羟基积雪草苷是积雪草由异戊二烯途径合成的皂苷类次生植物代谢产物。天然衍生化合物在生物医药领域通常具有广泛的生物学活性,在临床与日常生活中亦具有较广泛的应用。Centella asiatica (L.) Urban is a perennial herb of Umbelliferae, containing amino acids, flavonoids, triterpenoids and other components. Madecassoside (MC) is the pentacyclic triterpenoid with the highest content in Centella asiatica, with a molecular formula of C 48 H 78 O 20 , a relative molecular mass of 975.13, and the appearance of white crystals. Madecassoside is a saponin secondary plant metabolite synthesized by Centella asiatica via the isoprene pathway. Naturally derived compounds usually have a wide range of biological activities in the field of biomedicine, and are also widely used in clinical and daily life.
针对羟基积雪草苷在保湿、抗氧化、促进伤口愈合等方面的功能及机制的研究已较成熟。目前,它已被广泛用于湿巾、护肤品软膏类药品等日常生活用品的生产和对皮肤疾病的治疗,是治疗伤口、湿疹、痤疮、增生性瘢痕、烧伤性瘢痕、硬皮病和银屑病等皮肤疾病的高效药物。而在儿童日用护肤的研究领域,针对于儿童肌肤的脆弱敏感进行修护的功效研究还比较少。Research on the function and mechanism of madecassoside in moisturizing, anti-oxidation, and promoting wound healing has been relatively mature. At present, it has been widely used in the production of daily necessities such as wet wipes, skin care products, ointments, and medicines, and in the treatment of skin diseases. Highly effective drug for skin diseases such as psoriasis. In the research field of children's daily skin care, there are still relatively few researches on the efficacy of repairing children's fragile and sensitive skin.
发明内容Contents of the invention
针对现有技术中存在的不足之处,本发明的目的是提供一种具有多重修护功效的羟基积雪草苷的提取工艺及应用,获得不同舒缓修护功效体现的羟基积雪草苷,纯度高,安全无刺激,特别适合应用在儿童保湿及多重修护功效的护理产品中。为了实现根据本发明的上述目的和其他优点,提供了一种具有多重修护功效的羟基积雪草苷的提取工艺,包括:In view of the deficiencies in the prior art, the purpose of the present invention is to provide an extraction process and application of madecassoside with multiple repairing effects, and to obtain madecassoside with different soothing and repairing effects. High purity, safe and non-irritating, especially suitable for use in children's moisturizing and multiple repairing care products. In order to achieve the above object and other advantages according to the present invention, a process for extracting madecassoside with multiple repairing effects is provided, including:
S1、将积雪草全草粉碎进行搅拌提取;S1, pulverizing the whole centella asiatica and stirring and extracting;
S2、通过压滤,并进行药液上树脂柱吸附,用乙醇将有效成分从树脂柱洗脱出来;S2, through pressure filtration, and carry out resin column adsorption on medicinal liquid, elute active ingredient from resin column with ethanol;
S3、通过将药液上脱色树脂柱,对药液进行脱色,脱色液经刮板浓缩器浓缩至稠膏;S3. Decolorizing the medicinal liquid by putting the medicinal liquid on the decolorizing resin column, and the decolorizing liquid is concentrated to a thick paste through a scraper concentrator;
S4、转至D级洁净区的微波干燥箱进行烘干;S4, transfer to the microwave drying oven in the D-level clean area for drying;
S5、通过粉碎、过筛、总混,即得积雪草总苷;S5, by pulverizing, sieving, and blending, total asiaticosides are obtained;
S6、将乙醇溶解分离积雪草苷,得到羟基积雪草苷粗品;S6, dissolving and separating asiaticoside in ethanol to obtain a crude product of madecassoside;
S7、通过95%乙醇溶解精制,烘干,粉碎过筛网后,即得羟基积雪草苷。S7. Dissolving and refining with 95% ethanol, drying, pulverizing and passing through a sieve to obtain madecassoside.
优选的,步骤S1中将将积雪草全草粉碎至60目细粉,投入提取罐中,每罐900kg细粉,加入4.5吨沸水搅拌提取2小时。Preferably, in step S1, the whole centella asiatica is crushed into 60-mesh fine powder, put into extraction tanks, 900 kg of fine powder per tank, and 4.5 tons of boiling water is added to stir and extract for 2 hours.
优选的,步骤S5与步骤S7中的过筛均为100目。Preferably, the sieves in step S5 and step S7 are both 100 mesh.
优选的,步骤S6中的乙醇为5倍95%乙醇。Preferably, the ethanol in step S6 is 5 times 95% ethanol.
优选的,提取的羟基积雪草苷的质量分为1%-100%,其中羟基积雪草苷的质量分为95%的产品添加浓度为0.2%-0.04%。Preferably, the mass fraction of the extracted madecassoside is 1%-100%, wherein the product with a mass fraction of 95% madecassoside is added at a concentration of 0.2%-0.04%.
优选的,提取的羟基积雪草苷的质量分为1%-10%,其中羟基积雪草苷的质量分为10%的产品添加浓度为0.1%-0.6%。Preferably, the mass fraction of the extracted madecassoside is 1%-10%, wherein the product with a mass fraction of 10% madecassoside is added at a concentration of 0.1%-0.6%.
羟基积雪草苷在制备抗过敏产品中的应用。Application of madecassoside in the preparation of antiallergic products.
羟基积雪草苷在制备化学灼伤修护产品中的应用。Application of madecassoside in the preparation of chemical burn repair products.
本发明与现有技术相比,其有益效果是:通过本申请的制备工艺提取出的羟基积雪草苷,可制备成任意不同比例的羟基积雪草苷,获得不同舒缓修护功效体现的羟基积雪草苷,纯度高,安全无刺激,特别适合应用在儿童保湿及多重修护功效的护理产品中。Compared with the prior art, the present invention has the beneficial effect that: the madecassoside extracted by the preparation process of the present application can be prepared into madecassoside in any different proportions, and different soothing and repairing effects can be obtained. Madecassoside has high purity, is safe and non-irritating, and is especially suitable for use in children's moisturizing and multiple repairing care products.
附图说明Description of drawings
图1为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的斑马鱼胚胎中性粒细胞抑制测试流程图;Fig. 1 is the flow chart of the zebrafish embryo neutrophil inhibition test of the extraction process and application of madecassoside with multiple repairing effects according to the present invention;
图2为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的95%的羟基积雪草苷的修护效果图;Fig. 2 is an extraction process of madecassoside with multiple repairing effects according to the present invention and a repairing effect diagram of 95% madecassoside;
图3为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.1%的舒缓功效测试图;Fig. 3 is according to the extracting process of madecassoside with multiple repairing effects according to the present invention and the soothing efficacy test chart with the concentration of Centella asiatica extract applied at 0.1%;
图4为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.1%的舒缓功效柱状图;Fig. 4 is a histogram of the soothing efficacy of the extraction process of madecassoside with multiple repairing effects and the applied centella asiatica extract concentration of 0.1% according to the present invention;
图5为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.3%的舒缓功效测试图;Fig. 5 is an extraction process of madecassoside with multiple repairing effects according to the present invention and a test chart of the soothing efficacy of the applied centella asiatica extract at a concentration of 0.3%;
图6为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.3%的舒缓功效柱状图;Fig. 6 is a histogram of the soothing effect of the extraction process of madecassoside with multiple repairing effects and the applied centella asiatica extract concentration of 0.3% according to the present invention;
图7为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.6%的舒缓功效测试图;Fig. 7 is an extraction process of madecassoside with multiple repairing effects according to the present invention and a test chart of the soothing effect of the applied centella asiatica extract at a concentration of 0.6%;
图8为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的积雪草提取物浓度为0.6%的舒缓功效柱状图;Fig. 8 is a histogram of the soothing effect of the extraction process of madecassoside with multiple repairing effects and the applied centella asiatica extract concentration of 0.6% according to the present invention;
图9为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的羟基积雪草苷在过敏修护的实验图;Fig. 9 is an extraction process of madecassoside with multiple repairing effects according to the present invention and an experimental diagram of the applied madecassoside in allergy repair;
图10为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的羟基积雪草苷在化学灼伤修护的实验图;Fig. 10 is an experimental diagram of the extraction process of madecassoside with multiple repairing effects and the application of madecassoside in chemical burn repair according to the present invention;
图11为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的95%羟基积雪草苷的色谱图;Fig. 11 is an extraction process of madecassoside with multiple repairing effects according to the present invention and a chromatogram of 95% madecassoside;
图12为根据本发明的具有多重修护功效的羟基积雪草苷的提取工艺及应用的90%羟基积雪草苷的色谱图。Fig. 12 is a chromatogram of the extraction process of madecassoside with multiple repairing effects and the applied 90% madecassoside according to the present invention.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some, not all, embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
参照图1-12,一种具有多重修护功效的羟基积雪草苷的提取工艺,包括:S1、将积雪草全草粉碎进行搅拌提取;Referring to Figure 1-12, an extraction process of madecassoside with multiple repairing effects, including: S1, crushing the whole Centella asiatica and stirring to extract;
S2、通过压滤,并进行药液上树脂柱吸附,用乙醇将有效成分从树脂柱洗脱出来;S2, through pressure filtration, and carry out resin column adsorption on medicinal liquid, elute active ingredient from resin column with ethanol;
S3、通过将药液上脱色树脂柱,对药液进行脱色,脱色液经刮板浓缩器浓缩至稠膏;S3. Decolorizing the medicinal liquid by putting the medicinal liquid on the decolorizing resin column, and the decolorizing liquid is concentrated to a thick paste through a scraper concentrator;
S4、转至D级洁净区的微波干燥箱进行烘干;S4, transfer to the microwave drying oven in the D-level clean area for drying;
S5、通过粉碎、过筛、总混,即得积雪草总苷;S5, by pulverizing, sieving, and blending, total asiaticosides are obtained;
S6、将乙醇溶解分离积雪草苷,得到羟基积雪草苷粗品;S6, dissolving and separating asiaticoside in ethanol to obtain a crude product of madecassoside;
S7、通过95%乙醇溶解精制,烘干,粉碎过筛网后,即得羟基积雪草苷,根据图11-12为羟基积雪草苷的色谱图,其中如下分别是95%羟基积雪草苷的峰表与90%羟基积雪草苷的峰表:S7. Dissolve and refine with 95% ethanol, dry, crush and pass through a sieve to obtain madecassoside. According to Figure 11-12, it is the chromatogram of madecassoside, in which the following are 95% centella asiaticoside The peak table of glucoside and 90% madecassoside:
<峰表><peak table>
检测器A205nmDetector A205nm
<峰表><peak table>
检测器A205nmDetector A205nm
优选的,步骤S1中将将积雪草全草粉碎至60目细粉,投入提取罐中,每罐900kg细粉,加入4.5吨沸水搅拌提取2小时。Preferably, in step S1, the whole centella asiatica is crushed into 60-mesh fine powder, put into extraction tanks, 900 kg of fine powder per tank, and 4.5 tons of boiling water is added to stir and extract for 2 hours.
优选的,步骤S5与步骤S7中的过筛均为100目。Preferably, the sieves in step S5 and step S7 are both 100 mesh.
优选的,步骤S6中的乙醇为5倍95%乙醇。Preferably, the ethanol in step S6 is 5 times 95% ethanol.
优选的,提取的羟基积雪草苷的质量分为1%-100%,其中羟基积雪草苷的质量分为95%的产品添加浓度为0.2%-0.04%。Preferably, the mass fraction of the extracted madecassoside is 1%-100%, wherein the product with a mass fraction of 95% madecassoside is added at a concentration of 0.2%-0.04%.
优选的,提取的羟基积雪草苷的质量分为1%-10%,其中羟基积雪草苷的质量分为10%的产品添加浓度为0.1%-0.6%。Preferably, the mass fraction of the extracted madecassoside is 1%-10%, wherein the product with a mass fraction of 10% madecassoside is added at a concentration of 0.1%-0.6%.
羟基积雪草苷在制备抗过敏产品中的应用。Application of madecassoside in the preparation of antiallergic products.
羟基积雪草苷在制备化学灼伤修护产品中的应用。Application of madecassoside in the preparation of chemical burn repair products.
修护功效实验Repair Efficacy Experiment
一、化妆品修护效果筛查--斑马鱼胚胎中性粒细胞抑制测试方法1. Cosmetic repair effect screening--zebrafish embryo neutrophil inhibition test method
测试方法设计参照OECD TG 236标准。测试理论依据:BMC Biology.2010,8:151;JLeukoc Biol.2013,94(4):633-642;Molecules.2014,19(2):2390-2409,14:721-721。进行测试前,样品按照内部方法VI_SOP_002作为化妆品原料样品进行前处理。The test method design refers to the OECD TG 236 standard. Test theory basis: BMC Biology.2010,8:151; JLeukoc Biol.2013,94(4):633-642; Molecules.2014,19(2):2390-2409,14:721-721. Before testing, the samples are pre-treated as cosmetic raw material samples according to internal method VI_SOP_002.
1、术语和定义1. Terms and definitions
1.1斑马鱼胚胎Zebrafish embryo1.1 Zebrafish embryo Zebrafish embryo
处在依靠卵黄提供能量发育阶段的斑马鱼胚胎。A zebrafish embryo at the stage of development that relies on the yolk for energy.
1.2没有心跳Lack of heartbeat1.2 Lack of heartbeat
一分钟内心脏没有跳动的鱼胚胎。Fish embryos whose hearts did not beat for one minute.
1.3 10%致死浓度10% Lethal concentration,LC101.3 10%
受试物导致10%受试鱼胚胎死亡的浓度。鱼胚胎没有心跳则判定为死亡。The concentration of the test substance that causes the death of 10% of the tested fish embryos. Fish embryos without a heartbeat were judged dead.
2、原理2. Principle
斑马鱼胚胎的中性粒细胞和人体中性粒细胞在形态、生化和生理功能上高度相似。中性粒细胞是在损伤或病菌入侵部位第一批出现的白细胞,作用于清除感染或有害物质。应用硫酸铜诱导斑马鱼胚胎侧线区域神经丘细胞损伤而引起中性粒细胞聚集的模型进行测试,比较受试物处理组和模型对照组的鱼胚胎侧线区域的中性粒细胞的数量变化,计算中性粒细胞抑制率以评价原料、配方或产品的修护效果筛查。The neutrophils of zebrafish embryos and human neutrophils are highly similar in morphology, biochemistry and physiological function. Neutrophils are the first white blood cells to appear at the site of injury or bacterial invasion, and they work to clear infection or harmful substances. The model of neutrophil aggregation caused by copper sulfate-induced neuromast cell damage in the lateral line area of zebrafish embryos was used for testing, and the changes in the number of neutrophils in the lateral line area of fish embryos in the test substance treatment group and the model control group were compared, and calculated Neutrophil inhibition rate is used to evaluate the repair effect screening of raw materials, formulas or products.
3、仪器和设备3. Instruments and equipment
3.1斑马鱼养殖设备3.1 Zebrafish farming equipment
设备需配有温控装置,水循环和过滤装置,养殖容器用玻璃或常见食品级PC材质制成。可采用通用斑马鱼养殖设备或按实验室需求配备鱼缸(如长宽高45cm×45cm×30cm)。The equipment needs to be equipped with temperature control devices, water circulation and filtration devices, and the breeding containers are made of glass or common food-grade PC materials. General zebrafish breeding equipment can be used or fish tanks (such as length, width and height 45cm×45cm×30cm) can be equipped according to laboratory requirements.
3.2产卵盒/缸3.2 Spawning box/cylinder
由玻璃、不锈钢或其它惰性材料制成,配备网筛(网格大小为2mm×2mm,由不锈钢或多项材料组成用来保护鱼卵)。Made of glass, stainless steel or other inert materials, equipped with a mesh screen (mesh size is 2mm x 2mm, made of stainless steel or multiple materials to protect fish eggs).
3.3水质监测设备3.3 Water quality monitoring equipment
pH计、溶解氧测定仪、盐度计(电导率测定仪)。pH meter, dissolved oxygen meter, salinity meter (conductivity meter).
3.4分析天平3.4 Analytical balance
精度0.1mg。Accuracy 0.1mg.
3.5显微镜3.5 Microscope
配带照相系统,最大放大倍数应大于80倍的体式显微镜。Equipped with a camera system, the maximum magnification should be greater than 80 times the stereo microscope.
3.6测试容器3.6 Test container
测试容器:玻璃或聚苯乙烯测试容器(如6孔板,培养皿)。如测试物可能吸附于聚苯乙烯容器时(如非极性化学品),应选用惰性材料(如玻璃)来减少吸附。Test container: glass or polystyrene test container (eg 6-well plate, Petri dish). If the test substance may be adsorbed on the polystyrene container (such as non-polar chemicals), an inert material (such as glass) should be used to reduce the adsorption.
3.7恒温箱3.7 Thermostat
精度±1℃。Accuracy ±1°C.
3.8丰年虾孵化器3.8 Brine Shrimp Incubator
设备需配有孵化桶,气管,气量调节阀,气泵截止开关和止逆阀装置。The equipment needs to be equipped with incubator, air pipe, air volume regulating valve, air pump cut-off switch and check valve device.
3.9其他常规测试仪器和设备3.9 Other routine testing instruments and equipment
移液管、离心管、玻璃容器(如烧杯、容量瓶等)、旋涡混合仪、超声水浴锅、离心机、低温冰箱、可调节移液器和吸头。Pipettes, centrifuge tubes, glass containers (such as beakers, volumetric flasks, etc.), vortex mixers, ultrasonic water baths, centrifuges, cryogenic refrigerators, adjustable pipettes and tips.
4、主要试剂与耗材4. Main reagents and consumables
4.1水4.1 water
符合GB/T 6682规定。Comply with GB/T 6682 regulations.
4.2甲醇、二甲基亚砜、乙醇等助溶剂4.2 Methanol, dimethyl sulfoxide, ethanol and other co-solvents
分析纯级别。Analytical pure level.
4.3亲鱼养殖用水4.3 Water for Broodstock Breeding
称取4g海盐溶于10L水配制而成,盐度为0.25~0.50‰,电导率为500~800μS/cm,溶解氧80%饱和度,pH值6.5~8.5,硬度30~300mg/L(以碳酸钙计)。Weigh 4g of sea salt and dissolve it in 10L of water. The salinity is 0.25-0.50‰, the conductivity is 500-800μS/cm, the saturation of dissolved oxygen is 80%, the pH value is 6.5-8.5, and the hardness is 30-300mg/L (with Calcium Carbonate).
4.4丰年虾(Artemia salina)卵4.4 Eggs of brine shrimp (Artemia salina)
丰年虾休眠卵需干燥避光冷藏。称取约15g海盐溶于1L水配制丰年虾卵孵化水,密度以不超过4g/L丰年虾卵为宜。The dormant eggs of brine shrimp need to be kept dry and refrigerated away from light. Weigh about 15g of sea salt and dissolve it in 1L of water to prepare the hatching water for brine shrimp eggs. The density should not exceed 4g/L brine shrimp eggs.
4.5鱼胚胎培养液4.5 Fish embryo culture medium
称取2940mg无水氯化钙,1233mg七水硫酸镁,630mg碳酸氢钠,55mg氯化钾溶于10L水配制而成。pH值6.5~8.5。化学品均为分析纯级别。Weigh 2940mg of anhydrous calcium chloride, 1233mg of magnesium sulfate heptahydrate, 630mg of sodium bicarbonate, and 55mg of potassium chloride in 10L of water. The pH value is 6.5-8.5. Chemicals were of analytical grade.
4.6硫酸铜溶液4.6 Copper sulfate solution
用水配制159.6mg/L五水硫酸铜(CuSO4·5H2O)储存液。室温储存。Prepare 159.6 mg/L copper sulfate pentahydrate (CuSO4·5H2O) stock solution with water. Store at room temperature.
工作液浓度为0.1596mg/L,用鱼胚胎培养液稀释,使用前新鲜配制。The concentration of the working solution is 0.1596mg/L, diluted with fish embryo culture medium, and freshly prepared before use.
4.7吲哚美辛溶液4.7 Indomethacin solution
用二甲基亚砜配制35.78mg/L吲哚美辛储存液。冷藏。Prepare a 35.78 mg/L indomethacin stock solution with dimethyl sulfoxide. refrigeration.
工作液浓度为0.003578mg/L吲哚美辛,用鱼胚胎培养液稀释,使用前新鲜配制。The concentration of the working solution is 0.003578mg/L indomethacin, diluted with fish embryo culture medium, and freshly prepared before use.
4.8多聚甲醛4.8 Paraformaldehyde
用磷酸缓冲盐溶液(PBS)配制含有4%多聚甲醛和0.8%氢氧化钠(NAOH),pH为7.2~7.4的溶液。冷藏。A solution containing 4% paraformaldehyde and 0.8% sodium hydroxide (NAOH) with a pH of 7.2-7.4 was prepared with phosphate buffered saline (PBS). refrigeration.
4.9 50%和70%酒精溶液4.9 50% and 70% alcohol solutions
用水配制50%和70%酒精溶液。Prepare 50% and 70% alcohol solutions with water.
4.10苏丹黑染色液4.10 Sudan black staining solution
苏丹黑储存液:用70%酒精配制0.4%苏丹黑储存液。冷藏。Sudan black stock solution: prepare 0.4% Sudan black stock solution with 70% alcohol. refrigeration.
苯酚溶液:将8g苯酚溶于15mL乙醇溶液,将0.3g Na2HPO4·12H2O溶解于50mL水中,然后将二种溶液混合配制成苯酚溶液。室温储存,半年内有效。Phenol solution: Dissolve 8g phenol in 15mL ethanol solution, dissolve 0.3g Na2HPO4·12H2O in 50mL water, then mix the two solutions to prepare phenol solution. Store at room temperature, valid within half a year.
苏丹黑染色液是将900μL 70%酒精溶液,100μL苏丹黑儲存液和1μL苯酚溶液混合而成。Sudan black staining solution was prepared by mixing 900 μL 70% ethanol solution, 100 μL Sudan black stock solution and 1 μL phenol solution.
4.11PBST4.11 PBST
配制0.04% Triton X-100于PBS溶液中。室温储存。Prepare 0.04% Triton X-100 in PBS solution. Store at room temperature.
4.12漂白溶液4.12 Bleach solution
用水配制含有3% H2O2和1% KOH的溶液。使用前新鲜配制。Prepare a solution containing 3% H2O2 and 1% KOH with water. Prepare fresh before use.
4.13清透液14.13
用水配制含有20%甘油和0.25%KOH的溶液。室温保存。A solution containing 20% glycerol and 0.25% KOH was prepared in water. Store at room temperature.
4.14清透液24.14
用水配制含有50%甘油和0.25%KOH的溶液。室温保存。A solution containing 50% glycerol and 0.25% KOH was prepared in water. Store at room temperature.
5、实验方法5. Experimental method
5.1受试生物5.1 Test organisms
应用来源可靠(如中国国家斑马鱼资源中心)的野生型AB品系斑马鱼(Daniorerio)产卵测试。亲鱼应具有较好的繁殖能力–鱼龄以6~12月最佳。传代尽量使用侧交以保持遗传多样性,纯品系亲鱼繁殖5代后需更换新一批亲鱼。亲鱼不应该有明显可见的感染和疾病特征,且在2个月内没有经历过药物治疗。在繁殖产卵测试前,亲鱼应在引入实验室后驯养14天以上。Apply wild-type AB strain zebrafish (Daniorerio) spawning test from a reliable source (such as the National Zebrafish Resource Center of China). Broodstock should have good reproductive capacity – the best age for fish is from 6 to 12 months. Use side crossing as far as possible to maintain genetic diversity in subculture, and a new batch of broodstock should be replaced after 5 generations of pure line broodstock. Broodstock should have no visible signs of infection or disease and have not undergone medical treatment within 2 months. Broodstock should be domesticated for more than 14 days after introduction into the laboratory before breeding and spawning tests.
5.2养殖要求5.2 Breeding Requirements
5.2.1养殖水温宜控制在26~28.5℃,室内温度建议控制在20~25℃。5.2.1 The temperature of the breeding water should be controlled at 26-28.5°C, and the indoor temperature should be controlled at 20-25°C.
5.2.2养殖密度宜控制在每升水1~2条鱼,以及每日固定的12~16h光照,且需保持良好的过滤统。5.2.2 The breeding density should be controlled at 1 to 2 fish per liter of water, and a fixed 12 to 16 hours of light per day should be maintained, and a good filtration system should be maintained.
5.2.3每天至少喂食2次,包括至少1次丰年虾(Artemia salina)幼虫,喂食间隔在3小时以上,避免过量喂食影响水质和清洁度。5.2.3 Feed at least 2 times a day, including at least 1 brine shrimp (Artemia salina) larvae, and the feeding interval should be more than 3 hours to avoid overfeeding affecting water quality and cleanliness.
5.3产卵要求5.3 Spawn Requirements
5.3.1如用产卵缸收集鱼卵,将雄鱼和雌鱼以2:1的比率为宜在产卵前一天关灯前1~2h放进产卵缸中。由于斑马鱼偶尔不产卵,建议同时准备多个产卵缸备用。5.3.1 If a spawning tank is used to collect fish eggs, it is advisable to put male fish and female fish into the spawning tank at a ratio of 2:1 1-2 hours before turning off the lights the day before spawning. Since zebrafish do not spawn occasionally, it is recommended to prepare multiple spawning tanks for backup.
5.3.2为避免基因偏差,将最少3个产卵缸中收集的鱼卵混合再进行挑选备用。若用养殖鱼缸收集鱼卵,收卵盒在产卵前一天关灯前或产卵当天开灯前放进要收集鱼卵的养殖鱼缸中。5.3.2 In order to avoid genetic deviation, fish eggs collected in at least 3 spawning tanks are mixed and selected for later use. If fish eggs are collected in a breeding fish tank, the egg collection box is put into the breeding fish tank where the eggs are to be collected before turning off the lights on the day before spawning or before turning on the lights on the day of spawning.
5.3.3为避免鱼卵被成鱼所食,收卵盒用惰性网覆盖。5.3.3 In order to prevent fish eggs from being eaten by adult fish, the egg collection box is covered with an inert net.
5.3.4交配、产卵和受精在开灯后大约30min内完成,届时可把收卵盒移出鱼缸。5.3.4 Mating, spawning and fertilization are completed within about 30 minutes after turning on the light, and the egg collection box can be removed from the fish tank at that time.
5.3.5鱼卵从收卵盒取出后,建议用鱼胚胎培养液清洁鱼胚胎。5.3.5 After fish eggs are taken out of the egg collection box, it is recommended to clean the fish embryos with fish embryo culture solution.
5.3.6挑选健康的斑马鱼胚胎,并以200μL鱼胚胎培养液中不超过1粒鱼胚胎的密度于28℃培养至受精后3天。5.3.6 Select healthy zebrafish embryos and culture them at 28°C until 3 days after fertilization at a density of no more than one fish embryo in 200 μL fish embryo culture medium.
6、受试物准备6. Preparation of test substance
6.1化妆品原料6.1 Cosmetic Raw Materials
6.1.1水溶性原料:可用鱼胚胎培养液直接将受试物溶解配制成测试溶液。6.1.1 Water-soluble raw materials: fish embryo culture medium can be used to directly dissolve the test substance to prepare a test solution.
6.1.2非水溶性原料:可选常用溶剂如甲醇、二甲基亚砜、乙醇等助溶。如将受试物和有机溶剂按1:1(重量g:体积mL)混匀,超声处理10min,然后加入鱼胚胎培养液配制成所需浓度,震荡30s后于6500×g离心10min。取上清液进行测试。6.1.2 Non-water-soluble raw materials: common solvents such as methanol, dimethyl sulfoxide, ethanol, etc. can be used to aid in dissolution. For example, mix the test substance and organic solvent at a ratio of 1:1 (weight g: volume mL), sonicate for 10 minutes, then add fish embryo culture medium to prepare the required concentration, shake for 30 seconds, and then centrifuge at 6500×g for 10 minutes. Take the supernatant for testing.
6.2化妆品产品6.2 Cosmetic products
6.2.1水溶性产品:可用鱼胚胎培养液直接将受试物溶解配制成测试溶液。建议最高测试浓度为5g/L。6.2.1 Water-soluble products: the test substance can be directly dissolved in fish embryo culture medium to make a test solution. The recommended maximum test concentration is 5g/L.
6.2.2非水溶性产品:可选常用溶剂如甲醇、二甲基亚砜、乙醇等助溶。如将受试物和有机溶剂按1:1(重量g:体积mL)混匀,超声处理10min,然后加入鱼胚胎培养液配制成所需浓度,震荡30s后于6500×g离心10min。取上清液进行测试。建议最高测试浓度为5g/L。6.2.2 Non-water-soluble products: common solvents such as methanol, dimethyl sulfoxide, ethanol, etc. can be used to aid in dissolution. For example, mix the test substance and organic solvent at a ratio of 1:1 (weight g: volume mL), sonicate for 10 minutes, then add fish embryo culture medium to prepare the required concentration, shake for 30 seconds, and then centrifuge at 6500×g for 10 minutes. Take the supernatant for testing. The recommended maximum test concentration is 5g/L.
6.3注意事项6.3 Precautions
受试物测试溶液浓度需保证对斑马鱼胚胎的死亡率10%(没有心跳特征的胚胎界定为死亡)。测试时可根据需要设置多个浓度组。The concentration of the test substance test solution needs to ensure that the mortality rate of zebrafish embryos is 10% (embryos without heartbeat characteristics are defined as dead). Multiple concentration groups can be set as required during testing.
7、测试步骤7. Test steps
以下测试步骤是6-孔板测试指引。测试流程可参考图1。如应用更大的测试容器(如培养皿),测试指引需做相应调整。挑选健康的受精后3天大的斑马鱼胚胎。The following test procedure is a 6-well plate test guideline. Refer to Figure 1 for the testing process. If larger test containers (such as petri dishes) are used, the test guidelines need to be adjusted accordingly. Pick healthy zebrafish embryos that are 3 days post fertilization.
7.1测试分组7.1 Test grouping
测试需设定模型对照组(硫酸铜工作液)、阳性对照组(硫酸铜工作液+吲哚美辛工作液)和受试物组(硫酸铜工作液+受试物)。The test needs to set up a model control group (copper sulfate working solution), a positive control group (copper sulfate working solution + indomethacin working solution) and a test substance group (copper sulfate working solution + test substance).
7.2模型对照组设置7.2 Model control group settings
随机挑选20粒鱼胚胎,转移至3cm培养皿中,加入5mL含0.1596mg/L五水硫酸铜的鱼胚胎培养液(配制方法见4.6)。Randomly select 20 fish embryos, transfer them to a 3 cm petri dish, and add 5 mL of fish embryo culture medium containing 0.1596 mg/L copper sulfate pentahydrate (see 4.6 for the preparation method).
7.3阳性对照组设置7.3 Positive control group settings
随机挑选20粒鱼胚胎,转移至3cm培养皿中,加入5mL含0.1596mg/L五水硫酸铜0.003578mg/L吲哚美辛的鱼胚胎培养液(配制方法见4.6-4.7)。Randomly select 20 fish embryos, transfer them to a 3cm petri dish, and add 5mL of fish embryo culture solution containing 0.1596mg/L copper sulfate pentahydrate and 0.003578mg/L indomethacin (see 4.6-4.7 for the preparation method).
7.4受试物处理7.4 Test substance handling
随机挑选20粒鱼胚胎,转移至3cm培养皿中,加入5mL含0.1596mg/L五水硫酸铜和受试物的鱼胚胎培养液(配制方法见4.6和6.1-6.3)。放置于28±1℃恒温箱中培养40~45min。Randomly select 20 fish embryos, transfer them to a 3 cm petri dish, add 5 mL of fish embryo culture solution containing 0.1596 mg/L copper sulfate pentahydrate and the test substance (see 4.6 and 6.1-6.3 for the preparation method). Place in a 28±1°C incubator and incubate for 40 to 45 minutes.
7.5鱼胚胎固定染色7.5 Fixed staining of fish embryos
将每测试组鱼胚胎于多聚甲醛中固定至少1h后,用PBST(配制方法见6.11)处理鱼胚胎3次,每次5min,然后用50%乙醇(配制方法见4.9)处理3min。用苏丹黑染色溶液(配制方法见4.10)对鱼胚胎进行室温染色1h后,用70%乙醇(配制方法见4.9)浸洗4次,每次5min,然后用PBST处理2次,每次5min。用漂白溶液处理鱼胚胎10min,如在试管里处理,则需保持盖子打开。然后用70%乙醇溶液处理5min,PBST处理1min,用清澈液1(配制方法见4.13)处理15min,清澈液2(配制方法见4.14)处理10min,再用PBST处理3min。After the fish embryos of each test group were fixed in paraformaldehyde for at least 1 hour, the fish embryos were treated with PBST (see 6.11 for the preparation method) 3 times for 5 minutes each time, and then treated with 50% ethanol (see 4.9 for the preparation method) for 3 minutes. After staining the fish embryos with Sudan black staining solution (see 4.10 for the preparation method) at room temperature for 1 hour, soak them with 70% ethanol (see 4.9 for the preparation method) 4 times, 5 min each time, and then treat them with PBST twice, 5 min each time. Treat the fish embryos with bleach solution for 10 minutes, and keep the lid open if processing in a test tube. Then treat with 70% ethanol solution for 5 minutes, PBST for 1 minute, clear solution 1 (see 4.13 for the preparation method) for 15 minutes, clear solution 2 (see 4.14 for the preparation method) for 10 minutes, and then PBST for 3 minutes.
7.6样本的显微分析7.6 Microscopic analysis of samples
将鱼胚胎侧身摆放。然后放到体式显微镜下对鱼胚胎尾部进行拍照。Lay the fish embryo sideways. Then put it under a stereo microscope to take pictures of the fish embryo tail.
7.7数据和结果计算7.7 Data and calculation of results
计数每粒鱼胚胎从肛门起四分之三尾部侧线区域(见附录B图B)的中性粒细胞数目。Count the number of neutrophils in the lateral line region of the caudal three-quarters from the anus (see Appendix B, Figure B) of each fish embryo.
8、结果计算8. Result calculation
计算中性粒细胞抑制率:Calculate neutrophil suppression rate:
中性粒细胞抑制率=(C-T)/C×100%------------(1)Neutrophil inhibition rate=(C-T)/C×100% ------------(1)
(1)式中:(1) where:
T—受试物处理组鱼胚胎中性粒细胞数目的平均值;T—the average value of the number of neutrophils in fish embryos in the test substance treatment group;
C—模型对照组鱼胚胎中性粒细胞数目的平均值;C—the average number of neutrophils in fish embryos in the model control group;
对受试物处理组鱼胚胎中性粒细胞数目和模型对照组中性粒细胞数目进行双尾T检验,取得p值。The number of neutrophils in fish embryos in the test substance treatment group and the number of neutrophils in the model control group were carried out by two-tailed T-test, and the p value was obtained.
9、测试有效性验证9. Test validity verification
9.1测试判定9.1 Test Judgment
各测试组暴露完成后至少90%鱼胚胎存活,否则对应测试组结果无效。At least 90% of the fish embryos in each test group survived after exposure, otherwise the results of the corresponding test group were invalid.
9.2测试要求9.2 Test requirements
每批次测试须设置阳性对照组,要求每批次测试阳性对照组鱼胚胎中性粒细胞抑制率为正数且p<0.05。A positive control group must be set for each batch of tests, and the neutrophil inhibition rate of fish embryos in the positive control group for each batch of tests is required to be positive and p<0.05.
10、结果报告10. Results report
10.1中性粒细胞抑制率10.1 Neutrophil inhibition rate
受试物在对应测试浓度下对中性粒细胞的抑制率。The inhibitory rate of the test substance on neutrophils at the corresponding test concentration.
10.2评价10.2 Evaluation
评价受试物抑制中性粒细胞的能力,分析受试物处理组与模型对照组的检测值是否具有统计学差异(p<0.05)。Evaluate the ability of the test substance to inhibit neutrophils, and analyze whether there is a statistical difference between the test substance treatment group and the model control group (p<0.05).
11、结果相关性解读11. Interpretation of the correlation of results
在中性粒细胞抑制率为正数且具有统计学差异(p<0.05)情况下,测试结果可作为受试物具有修护效果的支持证据,但不替代人体功效测试。When the neutrophil inhibition rate is positive and has a statistical difference (p<0.05), the test results can be used as supporting evidence that the test substance has a repairing effect, but it is not a substitute for human efficacy testing.
注释:Notes:
1.斑马鱼胚胎中性粒细胞聚集模型:对斑马鱼胚胎进行CuSO4暴露诱导损伤制造中性粒细胞聚集模型。1. Zebrafish embryo neutrophil aggregation model: CuSO4 exposure-induced injury was performed on zebrafish embryos to create a neutrophil aggregation model.
2.斑马鱼胚胎中性粒细胞抑制率=[(模型对照组中性粒细胞数目-样品处理组中性粒细胞数目)×100/模型对照组中性粒细胞聚集数目]%。2. Zebrafish embryonic neutrophil inhibition rate=[(number of neutrophils in the model control group-number of neutrophils in the sample treatment group)×100/number of neutrophils in the model control group]%.
3.p值为样品处理组中性粒细胞数目和模型对照组中性粒细胞数目进行T-Test分析所得,一般定为p<0.05具有统计学显著差异。3. The p value is obtained from the T-Test analysis of the number of neutrophils in the sample treatment group and the number of neutrophils in the model control group, and it is generally determined that p<0.05 has a statistically significant difference.
4.根据样品对斑马鱼胚胎中性粒细胞抑制率以及抑制率的统计学差异,对样品的修护4. According to the statistical difference of the inhibition rate and the inhibition rate of the neutrophils in the zebrafish embryo, the repair of the sample
效果筛查进行评价,分为显著(抑制率为正数及p<0.05)和不显著(抑制率为负数或p≥0.05)。The effect screening was evaluated and divided into significant (inhibition rate was positive and p<0.05) and not significant (inhibition rate was negative or p≥0.05).
修护效果筛查结果代表性图片如下图:The representative pictures of repair effect screening results are as follows:
受试样品选择了95%的羟基积雪草苷,测试结果如图2,图2中分别为修护效果不显著、修护效果显著-30%中性粒细胞抑制率、VI-2021455S-1羟基积雪草苷95%﹕0.2%配方添加浓度,51%炎症细胞抑制率及VI-2021455S-1羟基积雪草苷95%﹕0.04%配方添加浓度,37%炎症细胞抑制率。95% madecassoside was selected as the tested sample, and the test results are shown in Figure 2. In Figure 2, the repair effect is not significant, the repair effect is significant-30% neutrophil inhibition rate, VI-2021455S- 1 Madecassoside 95%: 0.2% formula added concentration, 51% inflammatory cell inhibition rate and VI-2021455S-1 madecassoside 95%: 0.04% formula added concentration, 37% inflammatory cell inhibition rate.
(以下内容是否能写成实施例)(Whether the following content can be written as an embodiment)
选取不同添加浓度(0.1%、0.3%、0.6%)的羟基积雪草苷10%进行同样测试方法进行测试,得出以下舒缓修护的功效数据:
实施例1Example 1
将羟基积雪草苷10%稀释至0.1%的浓度进行舒缓修护测试,数据如下:Dilute madecassoside 10% to a concentration of 0.1% for soothing and repairing test, the data are as follows:
备注:客户指定往每个样品瓶内加入50mL的纯水制备测试样本。Remarks: The customer specifies to add 50mL of pure water to each sample bottle to prepare the test sample.
舒缓功效测试结果如图3-4,图3中分别为舒缓效果不显著、舒缓效果显著-30%中性粒细胞聚集抑制率、VI-20221477S-1积雪草提取物plusl0.1%-舒缓效果显著-46%中性粒细胞聚集抑制率,其中图4为舒缓功效测试结果柱状图。The results of the soothing effect test are shown in Figure 3-4. In Figure 3, the soothing effect is not significant, the soothing effect is significant-30% neutrophil aggregation inhibition rate, VI-20221477S-1 Centella asiatica extract plus10.1%-soothing Significant effect - 46% inhibition rate of neutrophil aggregation, wherein Fig. 4 is a histogram of soothing efficacy test results.
实施例2Example 2
将羟基积雪草苷10%稀释至0.3%的浓度进行舒缓修护测试,数据如下:Dilute madecassoside 10% to a concentration of 0.3% for soothing and repairing test, the data are as follows:
备注:客户指定往每个样品瓶内加入50mL的纯水制备测试样本。Remarks: The customer specifies to add 50mL of pure water to each sample bottle to prepare the test sample.
舒缓功效测试结果如图5-6,图5中分别为模型对照组:舒缓效果不显著-0%中性粒细胞聚集抑制率、阳性对照示例:0.0036mg/L吲哚美辛-舒缓效果显著-30%中性粒细胞聚集抑制率及受试样品组:VI-20221477S-2积雪草提取物plusl0.3%-舒缓效果显著39%中性粒细胞聚集抑制率,图6中为柱状图。The results of the soothing effect test are shown in Figures 5-6, and Figure 5 is the model control group: the soothing effect is not significant-0% neutrophil aggregation inhibition rate, and the positive control example: 0.0036mg/L indomethacin-significant soothing effect -30% neutrophil aggregation inhibition rate and test sample group: VI-20221477S-2 Centella asiatica extract plusl0.3% - significant soothing effect 39% neutrophil aggregation inhibition rate, columnar in Figure 6 picture.
实施例3Example 3
将羟基积雪草苷10%稀释至0.6%的浓度进行舒缓修护测试,数据如下:Dilute madecassoside 10% to a concentration of 0.6% for soothing and repairing test, the data are as follows:
备注:客户指定往每个样品瓶内加入50mL的纯水制备测试样本。Remarks: The customer specifies to add 50mL of pure water to each sample bottle to prepare the test sample.
舒缓功效测试结果如图7-8,图7中分别为模型对照组:舒缓效果不显著-0%中性粒细胞聚集抑制率、阳性对照示例:0.0036mg/L吲哚美辛-舒缓效果显著-30%中性粒细胞聚集抑制率及受试样品组:VI-20221477S-3积雪草提取物plusl0.6%-舒缓效果显著41%中性粒细胞聚集抑制率,图6中为柱状图。The results of the soothing effect test are shown in Figure 7-8. Figure 7 is the model control group: the soothing effect is not significant-0% neutrophil aggregation inhibition rate, and the positive control example: 0.0036mg/L indomethacin-significant soothing effect -30% neutrophil aggregation inhibition rate and test sample group: VI-20221477S-3 Centella asiatica extract plusl0.6% - significant soothing effect 41% neutrophil aggregation inhibition rate, columnar in Figure 6 picture.
二、过敏修护2. Allergy repair
本次测试案例中,测试者因对狗毛过敏,导致手部应激性反应,红肿且伴有瘙痒等炎症症状。测试者使用羟基积雪草苷10%配置成的乳液涂抹14天后,红肿消退且痒的症状也消失,如图9所示。In this test case, the tester was allergic to dog hair, resulting in irritative hand reactions, redness, swelling, and inflammatory symptoms such as itching. After the tester applied the emulsion formulated with madecassoside 10% for 14 days, the redness and swelling subsided and the itching symptoms also disappeared, as shown in FIG. 9 .
三、化学灼伤修护3. Chemical burn repair
本次测试案例中,测试者误用化学原料,导致化学灼伤,脸颊脱皮红肿,伴有强烈的灼烧感。将羟基积雪草苷5%的溶液进行涂抹观察灼伤修护状况。In this test case, the tester misused chemical raw materials, resulting in chemical burns, peeling and redness of the cheeks, accompanied by a strong burning sensation. Smear the 5% solution of madecassoside to observe the condition of burn repair.
据测试者反馈:According to tester feedback:
使用羟基积雪草苷的溶液2天后,灼烧感消退;After 2 days of using a solution of madecassoside, the burning sensation subsided;
使用7天后,灼伤部位红肿消失;After 7 days of use, the redness and swelling of the burn site disappeared;
使用14天后,脸部症状消失,恢复原状。如图10所示。After 14 days of use, the facial symptoms disappeared and returned to the original state. As shown in Figure 10.
这里说明的设备数量和处理规模是用来简化本发明的说明的,对本发明的应用、修改和变化对本领域的技术人员来说是显而易见的。The number of devices and processing scale described here are used to simplify the description of the present invention, and the application, modification and variation of the present invention will be obvious to those skilled in the art.
尽管本发明的实施方案已公开如上,但其并不仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的图例。Although the embodiment of the present invention has been disclosed as above, it is not limited to the use listed in the specification and implementation, it can be applied to various fields suitable for the present invention, and it can be easily understood by those skilled in the art Further modifications can be effected, so the invention is not limited to the specific details and examples shown and described herein without departing from the general concept defined by the claims and their equivalents.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211370486.9A CN115894597A (en) | 2022-11-03 | 2022-11-03 | Extraction process and application of madecassoside with multiple repair effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211370486.9A CN115894597A (en) | 2022-11-03 | 2022-11-03 | Extraction process and application of madecassoside with multiple repair effects |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115894597A true CN115894597A (en) | 2023-04-04 |
Family
ID=86470325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211370486.9A Pending CN115894597A (en) | 2022-11-03 | 2022-11-03 | Extraction process and application of madecassoside with multiple repair effects |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115894597A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948501A (en) * | 2010-09-01 | 2011-01-19 | 桂林莱茵生物科技股份有限公司 | Preparation method of hydroxyl asiaticoside |
CN104592341A (en) * | 2014-12-30 | 2015-05-06 | 广州白云山汉方现代药业有限公司 | Method for extracting asiaticoside and madecassoside from centella |
CN107903296A (en) * | 2017-11-29 | 2018-04-13 | 陶坤秀 | The extracting method of madecassoside |
CN108395464A (en) * | 2017-02-08 | 2018-08-14 | 桂林三金药业股份有限公司 | A method of preparing asiaticosid, madecassoside and Asaiticoside B from centella |
CN111285916A (en) * | 2020-02-14 | 2020-06-16 | 浏阳朗林生物科技有限公司 | Preparation method of centella asiatica extract with high content of total asiaticosides |
CN113171321A (en) * | 2021-05-11 | 2021-07-27 | 清远市望莎生物科技有限公司 | Centella asiatica extract and application thereof in preparation of anti-inflammatory cosmetics |
-
2022
- 2022-11-03 CN CN202211370486.9A patent/CN115894597A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948501A (en) * | 2010-09-01 | 2011-01-19 | 桂林莱茵生物科技股份有限公司 | Preparation method of hydroxyl asiaticoside |
CN104592341A (en) * | 2014-12-30 | 2015-05-06 | 广州白云山汉方现代药业有限公司 | Method for extracting asiaticoside and madecassoside from centella |
CN108395464A (en) * | 2017-02-08 | 2018-08-14 | 桂林三金药业股份有限公司 | A method of preparing asiaticosid, madecassoside and Asaiticoside B from centella |
CN107903296A (en) * | 2017-11-29 | 2018-04-13 | 陶坤秀 | The extracting method of madecassoside |
CN111285916A (en) * | 2020-02-14 | 2020-06-16 | 浏阳朗林生物科技有限公司 | Preparation method of centella asiatica extract with high content of total asiaticosides |
CN113171321A (en) * | 2021-05-11 | 2021-07-27 | 清远市望莎生物科技有限公司 | Centella asiatica extract and application thereof in preparation of anti-inflammatory cosmetics |
Non-Patent Citations (3)
Title |
---|
严明强;任娟;: "积雪草提取物在个人护理品中的应用", 香料香精化妆品, no. 06 * |
廖文贵;崔龙生;湛彩艳;郑佩静;: "一种高含量羟基积雪草苷在化妆品中的研究应用", 广东化工, no. 16 * |
祖士高;索邦丞;李萌;赵丹;王昌涛;王冬冬;: "积雪草活性成分及在化妆品中的应用", 日用化学品科学, no. 10 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100425258C (en) | Compound Chinese medicine composition and its prepn and use | |
CN115589988A (en) | A method for detecting the effect of whey protein concentrate on osteoporosis | |
CN115894597A (en) | Extraction process and application of madecassoside with multiple repair effects | |
CN108991292A (en) | Enhanced water resistance aquatic biological resisting stress food calling additive and preparation method | |
CN105123566A (en) | Hucho taimen sperm activation solution and preparation method thereof | |
CN115624512A (en) | Extraction method and application of centella asiatica with efficacy of removing red | |
Kumar et al. | Study on developmental toxicity and behavioral safety of Streblus asper Lour. bark on zebrafish embryos | |
CN104152404A (en) | Embryo heat resistance improving culture solution and using method thereof | |
CN110604823B (en) | A method for rapid screening of anti-glycation and/or anti-aging substances | |
Poesina et al. | Histopathological changes of renal tissue following sodium fluoride administration in two consecutive generations of mice. Correlation with the urinary elimination of fluoride | |
CN115998652A (en) | Centella asiatica extraction process with relieving and repairing effects | |
WO2023149794A1 (en) | Method for producing an active compound from lymantria dispar larvae | |
CN101099738B (en) | Application of sanguinarine in preparing aquatic animal medicine and method for preparing its preparation | |
CN103751755A (en) | Chinese herbal medicine biologic compound preparation for treating cow endometritis and preparation method thereof | |
CN115887274A (en) | Extraction process and application of madecassoside with acne skin repairing effect | |
CN105999303A (en) | Method for screening active compounds capable of adjusting gastrointestinal motility of zebrafish | |
CN106929560A (en) | A kind of method for determining chemicals development toxicity using tropical Xenopus Embryo | |
CN115944567A (en) | Centella asiatica extraction method with anti-inflammatory effect and application | |
RU2420212C1 (en) | Supporting therapy remedy and method for its production from frozen sea urchin spawn | |
CN111869676A (en) | Cypermethrin/chlorpyrifos calcium carbonate sustained and controlled release agent and preparation method thereof | |
CN1839922A (en) | Traditional Chinese medicine preparation for treating leukoderma, psoriasis and its preparation method | |
CN110538185A (en) | Application of sea cucumber phospholipids in the preparation of anti-inflammatory drugs | |
CN108849771A (en) | Peony bud is in the application extended in the nematode service life | |
CN114469932B (en) | 4-butene arctigenin and application thereof in killing fish ectoparasites | |
Fadzil et al. | Toxicity Assessment of Colloidal Nanofertilizers Using Zebrafish Embryo Model through Acute Toxicity Assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230404 |